To observe the therapeutic effects of Yiqi Jianpi Decoction combined with lentinan in patients with high-risk breast cancer.Methods:A total of 97 patients with high-risk breast cancer who were admitted to Clifford Hospital of Guangzhou University of Chinese Medicine from February 2016 to February 2018 were selected as the research objects，and were divided into a control group (n=48) and a study group (n=49) according to random number table method.The control group used conventional chemotherapy，and the observation group was given Yiqi Jianpi Decoction combined with lentinan Clinical efficacy，T lymphocyte subsets，inflammatory factors，tumor metastasis and infiltration factors and adverse reactions were compared.Results:After treatment，the total effective rate of the observation group was higher than that of the control group (63.26% vs 41.67% ); the levels of CD8+ in the 2 groups increased，but that in the study group was lower than that in the control group (P<0.05); the levels of CD3+，CD4+，CD4+/CD8+ in the 2 groups all decreased，but those in the study group were higher than those in the control group (all P<0.05); the levels of interleukin-17 (IL-17)，interleukin-6 (IL-6)，tumor necrosis factor-α (TNF-α)，vascular endothelial growth factor-A (VEGF-A)，transforming growth factor-β (TGF-β)，matrix metalloproteinase-2 (MMP-2)，tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in the 2 groups were lower those before treatment，and those in the study group were lower than those in the control group (P<0.05).There was no significant difference in the incidence of adverse reactions between the 2 groups (P>0.05).Conclusion:Yiqi Jianpi Decoction combined with lentinan on the basis of conventional chemotherapy can improve therapeutic effects，effectively improve the immune function，reduce the level of inflammatory factors，and reduce the risk of metastasis and infiltration of tumors.